The abstract is read at the publisher; the summary is JClub's.
In pooled adults with acute FXa inhibitor–associated life-threatening hemorrhage treated with andexanet, arterial thrombotic events predict mortality (HR 2.68, 95% CI 1.64–4.36).
- Why it matters: Baseline predictors of thrombotic events after andexanet are needed because the drug lowers hematoma expansion yet carries thrombotic risk.
- What they did: Secondary pooled analyses of ANNEXA-I and ANNEXA-4 (741 participants) used stratified Cox models to test baseline associations with arterial or all thrombotic events and mortality, including a model linking arterial events to mortality via time-dependent covariates.
- The result: No baseline factors predicted all thrombotic events, but arterial events were linked to prior myocardial infarction (HR 2.64), high-dose eligibility (HR 2.44), female sex (HR 1.78), and age (HR per year 1.04); mortality was also linked to prior congestive heart failure (HR 2.53), intracerebral/intraventricular hemorrhage (HR 1.90), and age (HR per year 1.06).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.